Cargando…

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)

Expression of the TUSC2 tumor-suppressor gene in TUSC2-deficient NSCLC cells decreased PD-L1 expression and inhibited mTOR activity. Overexpressing TUSC2 or treatment with rapamycin resulted in similar inhibition of PD-L1 expression. Both TUSC2 and rapamycin decreased p70 and SK6 phosphorylation, su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Xiaobo, Zhao, Yang, Wang, Jing, Dai, Bingbing, Gentile, Emanuela, Lin, Jing, Pu, Xingxiang, Ji, Lin, Wu, Shuhong, Meraz, Ismail, Majidi, Mourad, Roth, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746095/ https://www.ncbi.nlm.nih.gov/pubmed/29296193 http://dx.doi.org/10.18632/oncotarget.22581

Ejemplares similares

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
por: Xiaobo, Cao, et al.
Publicado: (2016)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
por: Meng, Jieru, et al.
Publicado: (2013)

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy
por: Dai, Bingbing, et al.
Publicado: (2015)

Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics
por: Gentile, Emanuela, et al.
Publicado: (2017)

Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis
por: Deng, Ruxia, et al.
Publicado: (2022)

miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC
por: Jeon, Young-Jun, et al.
Publicado: (2018)

The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs
por: Rutnam, Zina Jeyapalan, et al.
Publicado: (2014)

LncRNA TUSC8 suppresses the proliferation and migration of esophageal cancer cells by downregulation of VEGFA
por: Hu, Rui, et al.
Publicado: (2021)

Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3
por: Kong, Li, et al.
Publicado: (2020)

Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
por: Ivanova, Alla V, et al.
Publicado: (2009)

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
por: Li, Hongyu, et al.
Publicado: (2015)

TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis
por: Liu, Fengqiong, et al.
Publicado: (2018)

Long non-coding RNA TUSC7 suppresses osteosarcoma by targeting miR-211
por: Cong, Menglin, et al.
Publicado: (2019)

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
por: Pu, Xingxiang, et al.
Publicado: (2018)

Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans
por: Lu, Charles, et al.
Publicado: (2012)

TUSC3: a novel tumour suppressor gene and its functional implications
por: Yu, Xinshuang, et al.
Publicado: (2017)

NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair Pathway
por: Jayachandran, Gitanjali, et al.
Publicado: (2010)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9
por: WU, LIN, et al.
Publicado: (2016)

Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis
por: Fan, Xiaoqiang, et al.
Publicado: (2016)

The microtubule polymerase Stu2 promotes oligomerization of the γ-TuSC for cytoplasmic microtubule nucleation
por: Gunzelmann, Judith, et al.
Publicado: (2018)

The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer
por: Zheng, Bo-Hao, et al.
Publicado: (2021)

Cell-cycle dependent phosphorylation of yeast pericentrin regulates γ-TuSC-mediated microtubule nucleation
por: Lin, Tien-chen, et al.
Publicado: (2014)

Correction: Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis
Publicado: (2016)

Two Sisters From Qatar With TUSC3 Genetic Mutation: Psychiatric Considerations
por: Albobali, Yahia, et al.
Publicado: (2021)

Tumor Suppressor Candidate 2 (TUSC2): Discovery, Functions, and Cancer Therapy
por: Arrigo, Austin, et al.
Publicado: (2023)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

TUSC3 as a potential biomarker for prognosis in clear cell renal cell carcinoma
por: Yan, Youji, et al.
Publicado: (2019)

TUSC3 Methylation in Peripheral Blood Cells as a Biomarker for Diagnosis of Colorectal Cancer
por: Siri, Goli, et al.
Publicado: (2023)

Microtubule nucleating γTuSC assembles structures with 13-fold microtubule-like symmetry
por: Kollman, Justin M., et al.
Publicado: (2010)

TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo
por: Horak, Peter, et al.
Publicado: (2014)

Over-Expression of Two Different Isoforms of Cattle TUSC5 Showed Opposite Effects on Adipogenesis
por: Xia, Han, et al.
Publicado: (2022)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

MOZART1 and γ-tubulin complex receptors are both required to turn γ-TuSC into an active microtubule nucleation template
por: Lin, Tien-chen, et al.
Publicado: (2016)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation
por: Xu, Xuting, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sm8lsd30mhbaqfrot1h9tcg9tm